---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-017438"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:36:00.044459+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma reports record Q4 and full year 2024 financial results with YUPELRI and TRELEGY milestones

## Summary
- YUPELRI US net sales reached $66.7M in Q4 2024 and $238.6M for full year, up 10% and 8% year-over-year, driven by increased customer demand.
- TRELEGY global net sales of $3.46B in FY 2024 triggered a $50M milestone from Royalty Pharma, received in February 2025.
- Company ended Q4 2024 with $88M cash, and CYPRESS study on track to enroll final patient by mid-2025.
- Q4 2024 total revenue was $18.8M from Viatris collaboration, with net loss of $15.5M and non-GAAP net loss of $2.5M.

## SEC filing metadata
- accession: 0001104659-25-017438
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465925017438/0001104659-25-017438-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465925017438/tm257513d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-017438
- JSON: https://secwatch.observer/filing/0001104659-25-017438.json
- Plain text: https://secwatch.observer/filing/0001104659-25-017438.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.